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[Bu+Mel] combinations did not show synergistic cytotoxicity.
However, a combination of [0.25 mM Clo + 3.5 nM Gem]
resulted in about 60% inhibition of proliferation of p53-wild
type NCI H929 andMM.1R cells; combination indexes¼ 0.1e
0.6 suggested strong synergism. Two p53-mutated MM cell
lines, RPMI 8226 and U266B1, were more resistant to these
drugs. For example, exposure to [0.4 mM Clo+30 nM Gem]
inhibited proliferation of RPMI 8226 only by 25%. To deter-
mine if the cytotoxicity of [Clo+Gem] is mediated by p53,
H929 and MM.1R cells were pre-exposed to a p53-inhibitor,
piﬁthrin a. More than 50% of the [Clo+Gem]-mediated
cytotoxicity was reversed. The level of p53-regulated pro-
apoptotic PUMA and p21 proteins increased with [Clo+Gem]
but the effects were reversed in the presence of piﬁthrin a.
ATM kinasewas activated, further supporting involvement of
the ATM-p53 pathway in activation of DNA-damage
response. Phosphorylation of deoxycytidine kinase (DCK)
increased, and proteins involved in DNA-repair and rRNA
productionwere down-regulated. The activation of apoptosis
is suggested by the cleavage of PARP1 and caspases 3 and 8.
Further, mitochondrial membrane potential (MMP)
decreased in cells exposed to [Clo+Gem] consistent with
increased levels of proapoptotic factors cytochrome c, AIF
and SMAC/DIABLO in the cytosol, suggesting mitochondrial
leaks. These results show that the mechanism of synergistic
cytotoxicity of [Clo+Gem] in p53-positive MM cells involves
activated DCK, DNA-damage response, decreased MMP,
inhibited DNA repair, and nucleolar stress through decreased
rRNA. We are determining the effects of [Clo+Gem] in
primary cell samples from MM patients; the data will be
presented and discussed. Our investigation provides a basis
for introducing nucleoside analog combination(s) in both
cytoreductive induction therapy and pre-ASCT therapy in
MM, and in individualizing therapy based on p53 status to
avoid subjecting patients to ineffective therapy.255
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Background: Standard therapy for multiple myeloma (MM)
includes initial autologous hematopoietic cell trans-
plantation (autoHCT1) but this is not curative and most
patients will relapse. Data on salvage autoHCT2 or allogeneic
HCT (alloHCT2) are limited and the optimal salvage strategy
is unknown.
Methods: This is a retrospective study of MM patients >18
years of age who relapsed after autoHCT1 and underwent
salvage autoHCT2 or alloHCT2 between 1995-2011 at our
institution. Tandem auto-autoHCT or auto-alloHCT were
excluded.
Results: Characteristics of autoHCT2 (N¼27) and alloHCT2
(N¼19) patients were not signiﬁcantly different except the
alloHCT2 median age was signiﬁcantly (P ¼ .002) lower (54
years) than for autoHCT2 (62 years) and more alloHCT2
patients had KPS  70% (P ¼ .031). Complete and very good
partial remission (CR/VGPR) improved from 7% to 56% after
autoHCT2 and from 26% to 37% after alloHCT2. Of 15 patients
with progressive disease (PD) at the time of autoHCT2, 5achieved CR/VGPR and 7 PR. Nonrelapse mortality (NRM) at
3 years was 3.7% for autoHCT2 and 5.3% for alloHCT2 (P ¼
.901). Median progression free survival (PFS) and overall
survival (OS) for autoHCT2 (19 months, 23 months) and
alloHCT2 (6 months, 19 months) were not signiﬁcantly
different. For those entering salvage autoHCT2 in PD, PFS at
3-years was 41.7% (15.2-68.1%) and OS at 3-years was 45%
(16.1-73.9%). On multivariate analysis, time from autoHCT1
to relapse <1year vs. 1year (HR 24.81 [95% CI 2.4-249.9])
and no maintenance therapy vs. given after autoHCT2 (HR
12.19 [95% CI 2.5-249.9] impacted OS after autoHCT2.
However, only time from autoHCT1 to relapse<1 year versus
1 year (HR 18.55 [95% CI 2.28-150.57]) impacted PFS after
autoHCT2. For alloHCT2, no factors impacted NRM, PFS or OS.
For thosewith relapse from autoHCT1<1 year versus1 year
undergoing autoHCT2, median OS was 15 months (1-53) vs.
not yet reached at 143months andmedian PFS was 5months
(1-49) vs. not yet reached at 88 months. Major causes of
death for alloHCT2 were PD (n¼ 5), GVHD (n¼3), while for
autoHCT2, PD (n¼10), infection (n¼3).
Conclusions: Salvage autoHCT2 and alloHCT2 are both
feasible for patients with post autoHCT1MM relapse. Relpase
 1 year from autoHCT1 predicts for better PFS and OS in the
autoHCT2 group. Those with progressive disease can also be
salvaged by autoHCT2. Maintenance therapy after autoHCT2
is beneﬁcial and should routinely be used.256
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Background: High dose chemotherapy followed by autolo-
gous stem cell transplantation (ASCT) is effective therapy for
patients with POEMS syndrome. However, treatment before
ASCT has not been standardized. In addition, patients are at
high risk for an engraftment syndrome (ES) after ASCT, which
is associated with morbidity. Lenalidomide has recently
emerged as therapeutic options in patients with POEMS
syndrome. The purpose of the present study is to evaluate
the role of lenalidomide before ASCT.
Patients: Between December 2005 and May 2011, 7 patients
(pts) with POEMS syndrome underwent ASCT at our insti-
tution (median age at ASCT: 54 years, range: 36-66).
Peripheral blood stem cell (PBSC) was collected using
cyclophosphamide (CY) and granulocyte colony-stimulating
factor (G-CSF). PBSCwas used in 6 pts, whereas bonemarrow
and PBSC were used in a patient. Patients were conditioned
using melphalan (L-PAM; 200mg/sqm: n¼5, 140mg/sqm:
n¼1, 100 mg/sqm: n¼1).
Results: Of 7 pts, 5 have achieved neurologic improvement
after ASCT and are alive with a median follow-up of 44
months (range, 20-81 months), whereas 2 were not evalu-
ated for response because of early death. Interestingly, 2 pts
who had received prior therapy, lenalidomide (Case6: 15-
20mg per day for 53days, Case7: 15mg per day for 15days),
have been alive without ES after ASCT. However, of 5 pts who
had not received lenalidomide, 4 pts had ES after ASCT and
consequently 2 pts died (5 and 7 months).
Case Age Sex Mobilization regimen Prior therapy ES Response after ASCT
Observation period
(months) Outcome
1 36 F CY+ GeCSF e No Yes 82 Alive
2 49 F CY+ GeCSF e Yes Yes 81 Alive
3 45 F CY+ GeCSF Dex Yes Yes 45 Alive
4 63 M CY+ GeCSF e Yes No 6 Dead
5 52 M CY+ GeCSF LePAM+PSL Yes No 7 Dead
6 66 F CY+ GeCSF Len No Yes 25 Alive
7 54 M CY+ GeCSF Len+Dex No Yes 20 Alive
Abstracts / Biol Blood Marrow Transplant 19 (2013) S233eS256 S241Conclusion: Lenalidomide has the advantage of being asso-
ciated with a much lower risk of peripheral neuropathy than
new agents such as bortezomib and thalidomide. In addition,
lenalidomide could result in successful ASCT without severe
ES through possible immunomodulating effects before ASCT.
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Fanconi anemia (FA) is an inherited bone marrow failure
syndrome that is associated with multiple congenital
anomalies and a predisposition to cancer, primarily acute
myeloid leukemia and oropharyngeal cancers. Acute
lymphoblastic leukemia (ALL) has also rarely been reported.
Because of their rarity, there is no consensus on how to treat
leukemias when they develop. We report an 8-year old boy
with FA, who developed high-risk pre-B ALL due to an
unfavorable DNA-index, and monosomy 7. Patient received
low-risk ALL induction chemotherapy (vincristine 1.5 mg/m2
iv, weekly  4; prednisone 40 mg/m2/day orally for 28-days
then tapered; Peg-asparaginase 2500 IU/m2 on day 3, intra-
thecal cytarabine on day 0, intrathecal methotrexate on day
14). Patient went in remission promptly by day 14. The
patient developed liver dysfunction and a fungal infection,
which were treated accordingly. Following induction, the
patient developed prolonged myelosuppression that
required regular platelet and PRBC transfusions. He was
treated with non-myelosuppressive post-induction chemo-
therapy for 6 months prior to stem cell transplantation (SCT).
His therapy consisted of two doses of Peg-asparaginase and
two courses of oral dexamethasone for 5 days each. During
this period, serial bone marrow biopsies showed that the
patient remained in remission. Moreover, cytogenetic anal-
ysis showed a disappearance of monosomy 7. Because the
patient had no matched donor, he was given T-cell depleted
haploidentical SCT from his mother. The patient's lymphoid
and myeloid donor cell chimerism was 100 % on day +47 of
SCT. The patient's condition was complicated by a severe
adenovirus infection to which he succumbed on day +60 post
SCT. In conclusion, there is no standard chemotherapy
treatment for patients with FA and ALL. Our patient's high-
risk ALL appeared to respond to low-risk induction and
minimal non-myelosuppressive post-induction chemo-
therapy. These observations suggest that minimal chemo-
therapymay be effective in these patientswhile awaiting SCT.258
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The lifelong health care cost of a patient with sickle cell
disease (SCD) is estimated at w$1 million (Kauf, AJH 2009).
Allogeneic stem cell transplantation (alloSCT) remains the
only curative option for SCD, but no data exists investigating
health care utilization related to alloSCT. We hypothesize
that alloSCT in children with SCD reduces health care utili-
zation in comparison to children with SCD who do not
receive alloSCT.
Financial data from 2002-2011 was analyzed across the
two groups. The health care utilization was determined
over three time periods: pre-alloSCT, during alloSCT (day
0 to day +365), and post-alloSCT. The control group con-
sisted of patients referred for alloSCT and/or HLA typed
without alloSCT. Subjects without inpatient or outpatient
visits during the study time periods were included in the
analysis with a value of 0. The number of inpatient/
outpatient visits was compared with Poisson regression
method, and health care cost was compared with un-paired
t-test.
The alloSCT and control cohorts included 26 patients
(mean age - 6.78yrs), and 47 patients (mean age - 5.15yrs),
respectively. The 3-yr EFS for patients receiving HLA
matched sibling alloSCT was 100% and 44.4% for unrelated
cord blood transplant recipients. The mean total cost per
patient during the alloSCT year was $414,000 inpatient and
$28,000 outpatient. The average monthly inpatient visits
were similar in pre and post-alloSCT time periods; while the
number of inpatient visits in the post-alloSCT period was
signiﬁcantly lower than the control group (0.03 0.10 vs.
0.130.13/month, P ¼ .0003). The average number of
outpatient visits was also signiﬁcantly lower post-alloSCT
compared to pre-alloSCT (1.081.05 vs. 3.844.33/month, P
< .0001). When compared to controls, the post-alloSCT
cohort had signiﬁcantly higher outpatient visits (1.08 1.05
vs. 0.260.29/month, P < .0001). Detailed health care utili-
zation is described in the table below.
This analysis indicates that post-alloSCT health care
utilization decreases when compared to pre-alloSCT.
However, this does not translate into decreased cost when
compared to controls. This may reﬂect the limitation of the
study period to identify the actual changes in utilization over
time. More detailed analysis is ongoing to determine vari-
ables contributing to the substantial alloSCT associated costs
and the long term change in costs over time.
